# MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

> **NCT03566199** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sabine Mueller, MD, PhD** · enrollment: 7 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Panobinostat Nanoparticle Formulation MTX110
- **DRUG:** Convection-Enhanced Delivery (CED)

## Key facts

- **NCT ID:** NCT03566199
- **Lead sponsor:** Sabine Mueller, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-22
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566199, "MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03566199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*